Biogen Bids for Sage Therapeutics

This is a news story, published by Yahoo Finance, that relates primarily to Sage Therapeutics Inc. news.

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

Focused Sage Therapeutics Stock

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Sage stock news, Sage news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Sage Therapeutics

Benzinga

•

Health

Sage Therapeutics stock is up 37.3% at $7.62 after Biogen offers $7.22 per share

Summary

Nutrition label

74% Informative

Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares not already owned by Biogen for $ 7.22 per share.

The deal included an upfront payment of $875 million and a $650 million equity investment.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech